Compare MLSS & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | NTRB |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 72.6M |
| IPO Year | 1996 | 2019 |
| Metric | MLSS | NTRB |
|---|---|---|
| Price | $0.42 | $6.91 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 70.1K | 60.9K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,973,982.00 | $2,036,651.00 |
| Revenue This Year | $12.64 | $30.17 |
| Revenue Next Year | $8.99 | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $2.80 |
| 52 Week High | $0.60 | $8.63 |
| Indicator | MLSS | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 77.57 |
| Support Level | $0.24 | $4.18 |
| Resistance Level | $0.44 | N/A |
| Average True Range (ATR) | 0.03 | 0.61 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 0.36 | 92.04 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.